ArticleImmunology2019

An agonistic anti-Toll-like receptor 4 monoclonal antibody as an effective adjuvant for cancer immunotherapy.

Hiroki Tsukamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.